Effectiveness and safety of intravitreal dexamethasone implant (ozurdex) in patients with diabetic macular edema: A real-world experience

Ophthalmologica

Volumn 241, Issue 1, 2018, Pages 9-16

  Mello Filho, Paulo ^a   Andrade, Gabriel ^a   Maia, Andre ^a   Maia, Mauricio ^a   Biccas Neto, Laurentino ^a   Muralha Neto, Acacio ^b   Moura Brasil, Oswaldo ^c   Minelli, Eduardo ^d   Dalloul, Claudio ^e   Iglicki, Matias ^f  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c Brazilian Institute of Ophthalmology (IBOL)   (Brazil)

^d HCLOE Clinic   (Brazil)

^e D'Olhos Hospital   (Brazil)

^f Private Office   (Argentina)

Author keywords

Anti vascular endothelial growth factor; Diabetic macular edema; Drug delivery; Vascular endothelial growth factor

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID;

ADULT; AGED; ARGENTINA; ARTICLE; BEST CORRECTED VISUAL ACUITY; BRAZIL; CATARACT; CENTRAL RETINAL THICKNESS; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPEN STUDY; RETROSPECTIVE STUDY; SIDE EFFECT; CLINICAL TRIAL; COMPLICATION; DIABETIC RETINOPATHY; DRUG IMPLANT; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME; VERY ELDERLY; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; DEXAMETHASONE; DIABETIC RETINOPATHY; DRUG IMPLANTS; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 85056595575     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000492132     Document Type: Article

References (31)

1. International Diabetes Federation. IDF Diabetes Atlas. 7th ed. 2015 [accessed 2017 September 23]. Available from: http://www. idf. org/diabetesatlas.
2. Bertoldi AD, Kanavos P, Franca GV, Carraro A, Tejada CA, Hallal PC, et al. Epidemiology, management, complications and costs associated with type 2 diabetes in Brazil: a comprehensive literature review. Global Health. 2013 Dec; 9(1): 62.
3. Klafke A, Duncan BB, Stevens A, Rosa RS, de Moura L, Malta D, et al. The decline in mortality due to acute complications of diabetes mellitus in Brazil, 1991-2010. BMC Public Health. 2015 Aug; 15(1): 772.
4. Kempen JH, O'Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, et al.; Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004 Apr; 122(4): 552-63.
5. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al.; Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012 Mar; 35(3): 556-64.
6. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995 Jan; 102(1): 7-16.
7. Virgili G, Parravano M, Menchini F, Evans JR. Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev. 2014 Oct; 10(10):CD007419.
8. Grover D, Li TJ, Chong CC. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev. 2008 Jan;(1):CD005656.
9. Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014 Dec; 121(12): 2473-81.
10. Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, et al.; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014 Oct; 121(10): 1904-14.
11. Gillies MC, Islam FM, Larsson J, Pasadhika S, Gaston C, Zhu M, et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clin Exp Ophthalmol. 2010 Aug; 38(6): 605-12.
12. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006 Sep; 113(9): 1533-8.
13. Dugel PU, Bandello F, Loewenstein A. Dexamethasone intravitreal implant in the treatment of diabetic macular edema. Clin Ophthalmol. 2015 Jul; 9: 1321-35.
14. Ciulla TA, Harris A, McIntyre N, Jonescu-Cuypers C. Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant. Expert Opin Pharmacother. 2014 May; 15(7): 953-9.
15. Alshahrani ST, Dolz-Marco R, Gallego-Pinazo R, Diaz-Llopis M, Arevalo JF; KKESH International Collaborative Retina Study Group. Intravitreal dexamethasone implant for the treatment of refractory macular edema in retinal vascular diseases: Results of the KKESH International Collaborative Retina Study Group. Retina. 2016 Jan; 36(1): 131-6.
16. Bonnin S, Dupas B, Sanharawi ME, Perol J, Erginay A, Tadayoni R, et al. Efficacy of dexamethasone intravitreal implant for the treatment of diabetic macular edema. Eur J Ophthalmol. 2015 Sep-Oct; 25(5): 448-53.
17. Gupta PC, Ram J. Dexamethasone implant in diabetic macular edema in real-life situations. Eye (Lond). 2016 Dec; 30(12): 1650.
18. Guigou S, Pommier S, Meyer F, Hajjar C, Merite PY, Parrat E, et al. Efficacy and Safety of Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema. Ophthalmologica. 2015; 233(3-4): 169-75. Spanish.
19. Jimenez-Gomez B, Gonzalez-Montpetit M, Fonollosa Calduch A, Orive Banuelos A, Valsero Franco S. [Effects of ozurdex on intraocular pressure. A real life clinical practice study]. Arch Soc Esp Oftalmol. 2015 Sep; 90(9): 421-5.
20. Lam WC, Albiani DA, Yoganathan P, Chen JC, Kherani A, Maberley DA, et al. Real-world assessment of intravitreal dexamethasone implant (0. 7 mg) in patients with macular edema: the CHROME study. Clin Ophthalmol. 2015 Jul; 9: 1255-68.
21. Holladay JT. Visual acuity measurements. J Cataract Refract Surg. 2004 Feb; 30(2): 287-90.
22. Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina. 2010 Jul-Aug; 30(7): 1046-50.
23. Dutra Medeiros M, Postorino M, Navarro R, Garcia-Arumi J, Mateo C, Corcostegui B. Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica. 2014; 231(3): 141-6.
24. Escobar-Barranco JJ, Pina-Marin B, Fernandez-Bonet M. Dexamethasone Implants in Patients with Naive or Refractory Diffuse Diabetic Macular Edema. Ophthalmologica. 2015; 233(3-4): 176-85.
25. Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R. Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory. J Diabetes Res. 2016; 2016: 2156273.
26. Isaac DL, Abud MB, Frantz KA, Rassi AR, Avila M. Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double-blind study. Acta Ophthalmol. 2012 Feb; 90(1): 56-60.
27. Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol. 2008 Jan; 92(1): 76-80.
28. Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, et al.; Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015 Mar; 372(13): 1193-203.
29. Gonzalez VH, Campbell J, Holekamp NM, Kiss S, Loewenstein A, Augustin AJ, et al. Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data. Am J Ophthalmol. 2016 Dec; 172: 72-9.
30. Ross EL, Hutton DW, Stein JD, Bressler NM, Jampol LM, Glassman AR; Diabetic Retinopathy Clinical Research Network. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis from the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial. JAMA Ophthalmol. 2016 Aug; 134(8): 888-96.
31. Querques G, Darvizeh F, Querques L, Capuano V, Bandello F, Souied EH. Assessment of the Real-Life Usage of Intravitreal Dexamethasone Implant in the Treatment of Chronic Diabetic Macular Edema in France. J Ocul Pharmacol Ther. 2016 Jul-Aug; 32(6): 383-9.